On October 5 2026, the Centers for Medicare and Medicaid Services formally began reconsideration of its national coverage determination for transcatheter aortic valve replacement. The review will address coverage for patients with aortic regurgitation ^[2]. Also that day, the White House confirmed a $90 one time payment for eligible Medicare Part B seniors will be distributed this month. Payments will be sent via direct deposit or mail to over 20 million eligible people. Funds will come from the Medicare Improvement Fund ^[5]. The Medicare Improvement Fund received $2 billion from Congress. It is intended for improvements to the Medicare fee for service program ^[6]. Mehmet Oz, head of Medicare and Medicaid, stated on October 5 that development of prescription drug price disclosure systems will begin in November 2026 ^[7]. Independence Blue Cross agreed the same day to a $22.5 million settlement. The settlement resolves allegations the insurer submitted inaccurate diagnosis codes to CMS between 2017 and 2021 ^[1]. CMS issued guidance the same day noting compliance with agency price transparency rules does not ensure a healthcare facility has met obligations under Section 5 of the FTC Act ^[4]. CMS reported approximately 20.8 million enrollees in Original Medicare Part B may access the reimbursement referenced in that day's announcements ^[3]. The Federal Register published four corrected Medicare payment and quality reporting rules on September 29 and 30 2026 ^{[8] [9]}. On September 28 2026, a bill to modify Medicare biosimilar price negotiation eligibility was referred to the Senate Finance Committee, per Congress.gov records ^[10].